Novavax faces uncertainty as FDA requests a new clinical trial for its COVID-19 vaccine, the last protein-based option in the ...

The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.

As Donald Trump hits his 100th day in office Tuesday, his imprint is everywhere. But the long-term impact is often unclear.

KYIV, Ukraine (AP) — President Donald Trump on Wednesday lashed out at Ukrainian President Volodymyr Zelenskyy, saying ...

Zoetis, Inc. ZTS is slated to report its first-quarter 2025 earnings on May 6, 2025, before the opening bell. The Zacks ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is ...

Sanofi signed a deal with Earendil Labs for $125 million upfront and $1.72 billion in milestone payments. Regeneron Pharmaceuticals signed a deal worth more than $3 billion with contract drug ...

Novavax is working closely with federal drug regulators to get full approval for its COVID shot The vaccine is the only ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Kennedy won Senate confirmation to his job, in part, by promising not to change the nation’s vaccine schedule. Since taking ...

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...